Trial Profile
A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Takeda
- 24 Sep 2019 Status changed from active, no longer recruiting to completed.
- 22 Apr 2019 Planned primary completion date changed from 4 Sep 2019 to 4 Aug 2019.
- 01 Oct 2018 Planned End Date changed from 4 Sep 2019 to 4 Aug 2019.